NCT03700515 is a NA clinical trial of Erythropoietin in Healthy, sponsored by Morten Hostrup, PhD.

Who is sponsoring NCT03700515?

NCT03700515 is sponsored by Morten Hostrup, PhD.

What drugs are being tested in NCT03700515?

Interventions in NCT03700515: Erythropoietin, Placebo.

Is NCT03700515 still recruiting?

NCT03700515 is currently status unknown. Last updated 25 September 2019.

Last reviewed 2019-09-25 · How we verify

NCT03700515

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exosome Proteomics to Detect EPO

Status unknown NA Last updated 25 September 2019

What this trial tests

NA trial testing Erythropoietin in Healthy in 72 participants. Status unknown.

Timeline

4 September 2019

Primary endpoint
15 October 2020

15 October 2020

Quick facts

Lead sponsor	Morten Hostrup, PhD
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	basic science
Enrollment	72
Start date	4 September 2019
Primary completion	15 October 2020
Estimated completion	15 October 2020
Sites	1 location across Denmark

Drugs / interventions tested

Erythropoietin — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Morten Hostrup, PhD — full company profile →

Who can join

Adults 18 to 45, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The role of exosomes in cell signalling has only recently been appreciated and is a hugely exciting and rapidly growing area, and combined with LC-MS/MS proteomics, can overcome traditional barriers to proteomics in doping applications. To our knowledge, no research has yet been undertaken to explore whether the highly promising combination of exosome proteomics has utility for rhEPO detection. The applications are extensive; the diagnostic value of differentially regulated proteins could be further validated against the existing IEF EPO WADA accredited tests using samples collected during this study, used to study altitude hypoxia versus exogenous EPO administration (WADA current targeted research 2017), investigated as a platform approach to ESA and HIF agents more generally, as well as facilitate development of direct ELISA high throughput tests.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications.
Huda MN, Nafiujjaman M, Deaguero IG, Okonkwo J, et al · · 2021 · cited 160× · PMID 33988964 · DOI 10.1021/acsbiomaterials.1c00217
Clinical applications for exosomes: Are we there yet?
Perocheau D, Touramanidou L, Gurung S, Gissen P, et al · · 2021 · cited 101× · PMID 33751579 · DOI 10.1111/bph.15432
Insight into the Functional Dynamics and Challenges of Exosomes in Pharmaceutical Innovation and Precision Medicine.
Sharma A, Yadav A, Nandy A, Ghatak S. · · 2024 · cited 40× · PMID 38931833 · DOI 10.3390/pharmaceutics16060709

Verify or expand the search:

Other trials of Erythropoietin

Trials testing the same drug.

NCT06983756 — " Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Out · not yet recruiting
NCT06590155 — Erythropoietin in HIE Neonate · EARLY_PHASE1 · not yet recruiting
NCT06542393 — PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG) · Phase 2 · recruiting
NCT05395195 — Erythropoietin for Neonatal Encephalopathy in LMIC (EMBRACE Trial) · Phase 3 · recruiting
NCT05300477 — Pharmacological Countermeasures for High Altitude · Phase 4 · active not recruiting

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Morten Hostrup, PhD trials

Trials by the same sponsor.

NCT07421024 — Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle · Phase 2 · not yet recruiting
NCT06188767 — Testosterone-induced Muscle Memory and Underlying Mechanisms · NA · recruiting
NCT06067100 — U-LABA/ICS Effects on Exercise Performance, Indacaterol · NA · recruiting
NCT06105671 — U-LABA/ICS Effects on Exercise Performance, Formoterol · NA · completed
NCT06077019 — Role of Lung Function for Exercise Capacity in Well-trained Individuals · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03700515 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Morten Hostrup, PhD
Last refreshed: 25 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03700515.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing